A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia

Coursen W Schneider; Scott W Penney; Alison M Helfrich; Kip R Hartman; Kenneth Lieuw

doi:10.1097/MPH.0000000000001961

A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia

Coursen W Schneider, Scott W Penney, Alison M Helfrich, Kip R Hartman, Kenneth Lieuw

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

The literature regarding coronavirus disease of 2019 (COVID-19) infection in pediatrics indicates that children have less severe clinical presentations and lower mortality rates. There remains limited data regarding hematologic sequelae in pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Romiplostim has shown a platelet response in pediatric patients with chronic immune thrombocytopenic purpura, and eltrombopag is proven to increase platelet counts in patients with inherited thrombocytopenia. We review SARS-CoV-2-associated thrombocytopenia and present a pediatric patient with acute on chronic thrombocytopenia in the setting of COVID-19 with subsequent platelet recovery using romiplostim.

Original language	English
Pages (from-to)	e788-e790
Journal	Journal of Pediatric Hematology/Oncology
Volume	43
Issue number	6
DOIs	https://doi.org/10.1097/MPH.0000000000001961
State	Published - 1 Aug 2021
Externally published	Yes

Keywords

COVID-19/complications
Child
Humans
Male
Receptors, Fc/therapeutic use
Recombinant Fusion Proteins/therapeutic use
SARS-CoV-2/isolation & purification
Thrombocytopenia/drug therapy
Thrombopoietin/therapeutic use

Access to Document

10.1097/MPH.0000000000001961

Cite this

@article{9273f0bff8244984be0ddac6a8ddbdf8,

title = "A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia",

abstract = "The literature regarding coronavirus disease of 2019 (COVID-19) infection in pediatrics indicates that children have less severe clinical presentations and lower mortality rates. There remains limited data regarding hematologic sequelae in pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Romiplostim has shown a platelet response in pediatric patients with chronic immune thrombocytopenic purpura, and eltrombopag is proven to increase platelet counts in patients with inherited thrombocytopenia. We review SARS-CoV-2-associated thrombocytopenia and present a pediatric patient with acute on chronic thrombocytopenia in the setting of COVID-19 with subsequent platelet recovery using romiplostim.",

keywords = "COVID-19/complications, Child, Humans, Male, Receptors, Fc/therapeutic use, Recombinant Fusion Proteins/therapeutic use, SARS-CoV-2/isolation & purification, Thrombocytopenia/drug therapy, Thrombopoietin/therapeutic use",

author = "Schneider, {Coursen W} and Penney, {Scott W} and Helfrich, {Alison M} and Hartman, {Kip R} and Kenneth Lieuw",

year = "2021",

month = aug,

day = "1",

doi = "10.1097/MPH.0000000000001961",

language = "English",

volume = "43",

pages = "e788--e790",

journal = "Journal of Pediatric Hematology/Oncology",

issn = "1077-4114",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - A Novel Use of Romiplostim for SARS-CoV-2-induced Thrombocytopenia

AU - Schneider, Coursen W

AU - Penney, Scott W

AU - Helfrich, Alison M

AU - Hartman, Kip R

AU - Lieuw, Kenneth

PY - 2021/8/1

Y1 - 2021/8/1

N2 - The literature regarding coronavirus disease of 2019 (COVID-19) infection in pediatrics indicates that children have less severe clinical presentations and lower mortality rates. There remains limited data regarding hematologic sequelae in pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Romiplostim has shown a platelet response in pediatric patients with chronic immune thrombocytopenic purpura, and eltrombopag is proven to increase platelet counts in patients with inherited thrombocytopenia. We review SARS-CoV-2-associated thrombocytopenia and present a pediatric patient with acute on chronic thrombocytopenia in the setting of COVID-19 with subsequent platelet recovery using romiplostim.

AB - The literature regarding coronavirus disease of 2019 (COVID-19) infection in pediatrics indicates that children have less severe clinical presentations and lower mortality rates. There remains limited data regarding hematologic sequelae in pediatric patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Romiplostim has shown a platelet response in pediatric patients with chronic immune thrombocytopenic purpura, and eltrombopag is proven to increase platelet counts in patients with inherited thrombocytopenia. We review SARS-CoV-2-associated thrombocytopenia and present a pediatric patient with acute on chronic thrombocytopenia in the setting of COVID-19 with subsequent platelet recovery using romiplostim.

KW - COVID-19/complications

KW - Child

KW - Humans

KW - Male

KW - Receptors, Fc/therapeutic use

KW - Recombinant Fusion Proteins/therapeutic use

KW - SARS-CoV-2/isolation & purification

KW - Thrombocytopenia/drug therapy

KW - Thrombopoietin/therapeutic use

U2 - 10.1097/MPH.0000000000001961

DO - 10.1097/MPH.0000000000001961

M3 - Article

C2 - 33003146

SN - 1077-4114

VL - 43

SP - e788-e790

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

IS - 6

ER -